SCHEMBL6405329

SCHEMBL6405329

O=C1COCCN1c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.49
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
PTGS2 P35354 2/20 0.42
PDCD1 Q15116 2/20 0.42
CD274 Q9NZQ7 2/20 0.42
ALOX5 P09917 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
MAP4K1 Q92918 2/20 0.40
PLD1 Q13393 1/20 0.40
EP300 Q09472 1/20 0.39
KAT2B Q92831 1/20 0.39
CHEK1 O14757 1/20 0.39
AURKA O14965 1/20 0.39
DAPK3 O43293 1/20 0.39
JAK2 O60674 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22775726 0.93 CRBN (0.43) CRBNALDH1A1KDM4EHPGDHSD17B10
SCHEMBL23940374 0.80 PTGS2 (0.40) KDM4EPTGS2
SCHEMBL12104232 0.78 CRBN (0.65) CRBNALDH1A1PDCD1CD274ALOX5
SCHEMBL29865274 0.77 PTGS2 (0.40) KDM4EPTGS2MAP4K1
SCHEMBL16094570 0.77 PTGS2 (0.42) PTGS2MAP4K1JAK2DYRK1ALRRK2
SCHEMBL6097270 0.77 CRBN (0.51) CRBNALDH1A1KDM4EHPGDHSD17B10
SCHEMBL3375677 0.76 F10 (0.40) ALDH1A1HPGDPTGS2MAP4K1
SCHEMBL1161089 0.75 CRBN (0.50) CRBNALDH1A1KDM4EPDCD1CD274
SCHEMBL15856221 0.75 AKR1C3 (0.50) ALDH1A1HPGDPTGS2MAP4K1
SCHEMBL20898722 0.75 PTGS2 (0.36) PTGS2MAP4K1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 EP disclosed
WO-2024233846-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES, INC. (US) 2024-11-14 WO disclosed
CN-115215816-B Synthesis method of lactam compound 普济生物科技(台州)有限公司 2024-02-02 CN disclosed
CN-115215816-A Synthesis method of lactam compound 普济生物科技(台州)有限公司 2022-10-21 CN disclosed
WO-2022218348-A1 METHOD FOR SYNTHESIZING LACTAM COMPOUNDS Seasons Biotechnology (Taizhou) Co., Ltd. (CN) 2022-10-20 WO disclosed
WO-2017121444-A1 QUINOLIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2017-07-20 WO disclosed
US-20050227980-A1 Aralkyl and aralkylidene heterocyclic lactam and imides PFIZER INC. 2005-10-13 US disclosed
US-20050227981-A1 Aralkyl and aralkylidene heterocyclic lactam and imides PFIZER INC 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227981-A1 Aralkyl and aralkylidene heterocyclic lactam and imides ARAF, MRPL21, ACSL3 CRBN 454/4885ALDH1A1 1132/4885KDM4E 988/4885
US-20050227980-A1 Aralkyl and aralkylidene heterocyclic lactam and imides ARAF, MRPL21, ACSL3 CRBN 454/4885ALDH1A1 1132/4885KDM4E 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.